Hester Biosciences Reports Stellar Q3 FY26 Performance with 140% PAT Surge
Ahmedabad-based animal healthcare company Hester Biosciences Limited has announced a remarkable financial performance for the third quarter of the fiscal year 2026. The company reported a 140% year-on-year increase in standalone profit after tax (PAT), which soared to Rs 10.67 crore for Q3 FY26, compared to Rs 4.44 crore in the same period last year. This impressive growth is attributed to enhanced execution capabilities and significant margin expansion across operations.
Revenue and Profitability Metrics Show Strong Growth
Revenue from operations witnessed a healthy rise of 12% YoY, reaching Rs 70.35 crore in Q3 FY26. The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) surged by 72% to Rs 17.75 crore, with EBITDA margins expanding substantially to 25% from 16% a year earlier. This margin improvement underscores Hester Biosciences' focus on operational efficiency and cost management. Additionally, earnings per share (EPS) for the quarter stood at Rs 12.54, reflecting robust shareholder value creation.
Strategic Initiatives and Capacity Expansion
During the quarter, Hester Biosciences capitalized on its fill-finish facility, effectively doubling drug product capacity. This strategic move enhances manufacturing flexibility, positioning the company to support future growth in both domestic and export markets. The company emphasized its commitment to strong operational discipline, achieved through controlled overheads, process standardization, and efficient manpower deployment, which have contributed to the improved financial outcomes.
Portfolio Strengthening with New Vaccine Licences
Post-quarter-end, Hester Biosciences received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine. This development strengthens the company's poultry vaccine portfolio, potentially opening new revenue streams and reinforcing its market position in the animal healthcare sector.
Nine-Month Performance and Outlook
For the nine months ended December 2025, standalone PAT increased by 16% YoY to Rs 25.72 crore. EBITDA for this period stood at Rs 44.46 crore, with margins improving to 22%. However, revenue declined to Rs 198.42 crore, primarily due to delays in government-led animal immunisation programmes. The company expects execution to pick up in the fourth quarter, indicating a positive outlook for the remainder of the fiscal year.
Hester Biosciences' Q3 FY26 results highlight its resilience and strategic growth initiatives in the competitive animal healthcare industry, with Ahmedabad serving as a key operational hub.
